Oncotelic Therapeutics (OTLC) Income from Non-Controlling Interests (2020 - 2026)
Oncotelic Therapeutics (OTLC) recorded Income from Non-Controlling Interests of -$47,136 in Q2 2026, compared with -$67,407 a year earlier.
Powered by 
Analysis
Oncotelic Therapeutics (OTLC) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
On a TTM basis, Oncotelic Therapeutics' Income from Non-Controlling Interests came in at -$236,505 as of Jun 30, 2026; for FY2025, it came in at -$254,917.
- Across earlier years, Income from Non-Controlling Interests came in at -$255,527 in FY2024, -$302,972 in FY2023, -$418,378 in FY2022 and -$1.13 million in FY2021.
- The Q2 2026 figure is the highest quarterly Income from Non-Controlling Interests since Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,109.83 Bn | 1,078.42 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 610.61 Bn | 529.14 Bn | 17.26 Bn | - |
| 3 | AbbVie | 500.66 Bn | 473.77 Bn | 12.70 Bn | 3.00 Mn |
| 4 | Merck | 354.64 Bn | 309.02 Bn | 12.21 Bn | -2.00 Mn |
| 5 | Novartis Ag | 291.14 Bn | 255.13 Bn | 11.24 Bn | -7.00 Mn |
| 6 | Astrazeneca | 254.18 Bn | 227.87 Bn | 12.86 Bn | 1.00 Mn |
| 7 | Amgen | 229.46 Bn | 184.86 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 190.33 Bn | 164.53 Bn | 6.22 Bn | - |
| 9 | Pfizer | 167.92 Bn | 114.57 Bn | 10.94 Bn | 10.00 Mn |
| 10 | Oncotelic Therapeutics | 8.28 Mn | 7.42 Mn | - | -47,136.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -47,136.00 |
| Dec 31, 2025 | -54,958.00 |
| Sep 30, 2025 | -67,004.00 |
| Jun 30, 2025 | -67,407.00 |
| Mar 31, 2025 | -65,548.00 |
| Dec 31, 2024 | -53,527.00 |
| Sep 30, 2024 | -67,165.00 |
| Jun 30, 2024 | -68,336.00 |
| Mar 31, 2024 | -66,499.00 |
| Dec 31, 2023 | -55,089.00 |
| Sep 30, 2023 | -74,248.00 |
| Jun 30, 2023 | -93,010.00 |
| Mar 31, 2023 | -80,625.00 |
| Dec 31, 2022 | -54,913.00 |
| Sep 30, 2022 | -81,501.00 |
| Jun 30, 2022 | -41,424.00 |
| Mar 31, 2022 | -240,540.00 |
| Dec 31, 2021 | -176,953.00 |
| Sep 30, 2021 | -293,001.00 |
| Jun 30, 2021 | -336,737.00 |
API Access
Oncotelic Therapeutics Income from Non-Controlling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=OTLC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "OTLC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=OTLC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();